Journal of mucopolysaccharidosis and rare diseases

Association for Research of MPS and Rare Diseases (뮤코다당증연구학회)
권호 표지
DOI QR코드

DOI QR Code

Insulin/GLP-1 Treatment for Patients with DM

  • Received : 2016.11.13
  • Accepted : 2016.11.23
  • Published : 2016.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Combining basal insulin therapy with a glucagon-like peptide-1 receptor agonist (GLP-1 RA) has clear clinical advantages, and is supported by the latest EASD/ADA position statement (1). IDegLira is a once-daily combination of the basal insulin, degludec, and the GLP-1RA, liraglutide, in one pen. The DUAL phase 3 clinical trial program provides important evidence about the efficacy and safety of IDegLira in three different populations of patients with type 2 diabetes (T2D): insulin naïve subjects uncontrolled on oral antidiabetic drugs (OADs), subjects uncontrolled on OAD(s) and a GLP-1 RA, and subjects uncontrolled on OAD(s) and basal insulin. Treatment with IDegLira reduced mean HbA1c to below the EASD/ADA treatment target of 7.0% in all five trials. The mean reduction of HbA1c from baseline ranged from 1.3% and 1.9%. IDegLira resulted in weight loss for subjects uncontrolled on basal insulin, was weight neutral for subjects on OADs and weight gain was minimal (2 kg) for subjects previously treated with a GLP-1 RA. Rates of hypoglycaemia were low across all the trials, particularly considering the level of glycaemic control achieved.

Keywords

References

  1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the study of diabetes. Diabetologia 2015;58:429-42. https://doi.org/10.1007/s00125-014-3460-0
  2. Davies MJ, Kela R, Khunti K. Liraglutide-overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes. Diabetes Obes Metab 2011;13:207-20. https://doi.org/10.1111/j.1463-1326.2010.01330.x
  3. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. Epub 2016 Jun 13. doi:10.1056/NEJMoa1603827.
  4. Heise T, Nosek L, Bottcher SG, Hastrup H, Haahr H. Ultralong-acting insulin degludec has a flat and stable glucoselowering effect in type 2 diabetes. Diabetes Obes Metab 2012;14:944-50. https://doi.org/10.1111/j.1463-1326.2012.01638.x
  5. Novo Nordisk A/S, $Xultophy^{(R)}$ Summary of Products characteristic (SPC). 2014 [cited 2016 Jul 12]. Available from: http://ec.europa.eu/ health/documents/community-register/2014/20140918129550/anx_129550_en.pdf.